361-72-8

Basic information

• Product Name: 3,5-DIFLUORO-2-NITROANILINE
• Synonyms: 3,5-DIFLUORO-2-NITROANILINE;3,5-Difluoro-2-nitro-phenylamine
• CAS NO: 361-72-8
• Molecular Formula: C₆H₄F₂N₂O₂
• Molecular Weight: 174.1
• Mol File: 361-72-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 306.6°Cat760mmHg
• Flash Point: 139.2°C
• Appearance: /
• Density: 1.554g/cm³
• Vapor Pressure: 0.000765mmHg at 25°C
• Refractive Index: 1.575
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 3,5-DIFLUORO-2-NITROANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-DIFLUORO-2-NITROANILINE(361-72-8)
• EPA Substance Registry System: 3,5-DIFLUORO-2-NITROANILINE(361-72-8)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 361-72-8(Hazardous Substances Data)

Usage

General Description

"3,5-Difluoro-2-nitroaniline" is a chemical compound that is commonly used in the field of organic synthesis, specifically as an intermediate in the production of various pharmaceutical products and organic compounds. Characterized by its systematic name, it is an aromatic compound that features an aniline group (-NH2) substituted with two fluorine atoms (F) and a nitro group (NO2). 3,5-DIFLUORO-2-NITROANILINE is relatively stable under normal temperatures and pressures, but it has the potential to release harmful gases or fumes if decomposed. Care and safety measures should be taken when handling, as it is potentially harmful if swallowed, inhaled, or comes in contact with the skin.

InChI:InChI=1/C6H4F2N2O2/c7-3-1-4(8)6(10(11)12)5(9)2-3/h1-2H,9H2

Upstream product

• 404-01-3 N-(3,5-difluorophenyl)acetamide 
• 1052686-55-1 2,2,2-trifluoro-N-(3,5-difluoro-2-nitrophenyl)acetamide 
• 361-71-7 3,5-difluoro-2-nitroacetanilide 
• 372-39-4 3,5-difluoroaniline 
• 315-14-0 1,3,5-trifluoro-2-nitrobenzene 

Downstream Products

• 1035388-12-5 5-fluoro-3-morpholino-2-nitroaniline 
• 934765-58-9 {3-fluoro-5-[(4-formylphenyl)oxy]-2-nitrophenyl}formamide 
• 934765-55-6 4-[(3-amino-5-fluoro-4-nitrophenyl)oxy]benzaldehyde 
• 1052686-56-2 5-fluoro-2-nitro-3-(1H-pyrazol-1-yl)benzenamine 
• 859536-42-8 5-fluoro-3-(2-methoxyphenoxy)-2-nitroaniline 
• 873662-28-3 5-fluoro-3-methoxybenzene-1,2-diamine 
• 2091140-87-1 3-fluoro-5-methoxy-2-nitroaniline 

Relevant articles and documents

Synthesis and Structural Investigation of Some Electron-Rich Nitroaromatics

2,4-Difluoro-, 2,4,6-Trifluoro-, and 2,3,4,6,tetrafluoronitrobenzenes undergo nucleophilic aromatic substitution, once, twice, and three times with a variety of amine substituents with a high degree of regiochemical control to provide a range of electron-

Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: Intelligent design and evolution through the judicious use of structure-guided design and stucture-activity relationships

The discovery of new antibacterial agents with novel mechanisms of action is necessary to overcome the problem of bacterial resistance that affects all currently used classes of antibiotics. Bacterial DNA gyrase and topoisomerase IV are well-characterized clinically validated targets of the fluoroquinolone antibiotics which exert their antibacterial activity through inhibition of the catalytic subunits. Inhibition of these targets through interaction with their ATP sites has been less clinically successful. The discovery and characterization of a new class of low molecular weight, synthetic inhibitors of gyrase and topoisomerase IV that bind to the ATP sites are presented. The benzimidazole ureas are dual targeting inhibitors of both enzymes and possess potent antibacterial activity against a wide spectrum of relevant pathogens responsible for hospital- and community-acquired infections. The discovery and optimization of this novel class of antibacterials by the use of structure-guided design, modeling, and structure-activity relationships are described. Data are presented for enzyme inhibition, antibacterial activity, and in vivo efficacy by oral and intravenous administration in two rodent infection models.